Authors
Marc van der Valk, John JP Kastelein, Robert L Murphy, Frank van Leth, Christine Katlama, Andrej Horban, Marshall Glesby, Georg Behrens, Bonaventura Clotet, Rebecca K Stellato, Henri OF Molhuizen, Peter Reiss, Atlantic Study Team
Publication date
2001/12/7
Journal
Aids
Volume
15
Issue
18
Pages
2407-2414
Publisher
LWW
Description
Background
Protease inhibitor-containing antiretroviral therapy for the treatment of HIV-1 infection is associated with elevated triglyceride and low-density lipoprotein (LDL)-cholesterol levels which may expose patients to an increased risk of coronary artery disease (CAD). We report the lipid and lipoprotein profiles of a representative subset of treatment-naive patients included in the Atlantic Study. This study compares patients treated with stavudine and didanosine plus the random addition of either the non-nucleoside reverse transcriptase inhibitor nevirapine (NVP), the protease inhibitor indinavir or the nucleoside reverse transcriptase inhibitor lamivudine.
Methods
Lipids and lipoproteins were quantified from prospectively collected and cryopreserved plasma samples obtained at weeks 0, 6 and 24.
Results
We observed a striking increase in high-density lipoprotein (HDL)-cholesterol (49%), apolipoprotein AI (19 …
Total citations
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024203733272515282113221413118105521163
Scholar articles
M van der Valk, JJP Kastelein, RL Murphy, F van Leth… - Aids, 2001